CME Review ArticleRapid Diagnostic Tests for Meningitis and Encephalitis—BioFireFleischer, Eduardo MD∗; Aronson, Paul L. MD, MHS†,‡Author Information From the ∗Medical Student, Yale School of Medicine †Associate Professor of Pediatrics and of Emergency Medicine ‡Deputy Director, Pediatric Residency Program, Section of Pediatric Emergency Medicine, Departments of Pediatrics and of Emergency Medicine, Yale School of Medicine, New Haven, CT. E.F. is now a Resident Physician at Boston Combined Residency Program, Boston, MA. P.L.A. is supported by grant K08HS026006 from the Agency for Healthcare Research and Quality (AHRQ). The content is solely the responsibility of the authors and does not represent the official views of AHRQ. Lippincott CME Institute has identified and resolved all conflicts of interest concerning this educational activity. The authors, faculty, and staff in a position to control the content of this CME activity and their spouses/life partners (if any) have disclosed that they have no financial relationships with, or financial interest in, any commercial organizations relevant to this educational activity. Reprints: Paul L. Aronson, MD, MHS, Section of Pediatric Emergency Medicine, Yale School of Medicine, 100 York St, Suite 1F, New Haven, CT 06511 (e-mail: email@example.com). Pediatric Emergency Care: August 2020 - Volume 36 - Issue 8 - p 397-401 doi: 10.1097/PEC.0000000000002180 Buy Take the CME Test Metrics Abstract Meningitis and encephalitis (ME) are important causes of morbidity and mortality worldwide. Patients suspected of having ME are often hospitalized and started on empiric antimicrobial treatment, because of the potential adverse consequences of delaying the diagnosis or treatment. Multiplexed polymerase chain reaction panels are one of several rapid diagnostic technologies that have the potential to overcome some of the limitations of conventional diagnostic methods for ME. The BioFire FilmArray Meningitis/Encephalitis Panel was the first Food and Drug Administration–cleared multiplex polymerase chain reaction for the evaluation of cerebrospinal fluid samples, able to identify 14 organisms in a single test reaction. This newer rapid diagnostic tool has an overall high sensitivity and specificity for the diagnosis of ME with a fast turnaround time and has the potential to improve resource utilization for patients presenting with suspicion of ME. However, further research is needed to determine its optimal use in the evaluation of patients with suspected ME. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.